Conclusions
Based on our findings, our study is the first time to describe the novel
function of PDIA4 and we propose a new linkage between PDIA4 and various
immune components in glioma. PDIA4 is highly expressed in glioma and
significantly related with the clinical outcomes. The tumor promoting
character of PDIA4 is potentially mediated by the immune system because
of the certain connections with multiple immune factors in the glioma
TME. The detailed molecular mechanism of PDIA4 and the development of
glioma need to be further illustrated. To this end, our study provides
novel possibilities for future discoveries to find new therapeutic
approaches by targeting PDIA4 for immunotherapy in glioma.